Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/07/22
End: 03/16/24
Due: 03/16/25
Phase: N/A
Priority: Normal
Start: 03/31/25
End: 06/30/26
Due: 06/30/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa. | NCT05378997 | Xinnate AB | user2@example.com | None | 2022-04-07 | 2024-03-16 | 2025-03-16 | - | - | 2025-07-14 |
| A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, STEP-study | NCT06594393 | Xinnate AB | user2@example.com | None | 2025-03-31 | 2026-06-30 | 2027-06-30 | - | - | 2025-07-14 |